Compare Enact Holdings Inc (ACT) vs Core Scientific Inc (CORZ) Price & Performance

ACT trades at $49.54, up 2.14% today, near the consensus price target of $49.00. The stock shows strong profitability with a net income margin of 54.51% and a P/E ratio of 10.36, indicating potential undervaluation. Recent Q2 2026 earnings beat estimates at $1.26 per share. Technical indicators signal a bullish trend, though RSI levels suggest overbought conditions. The company maintains stable dividends, with a $0.24 payout scheduled for September 2026.

Outlook is cautiously optimistic with solid fundamentals and analyst support, but risks include reliance on steady earnings growth and market volatility. The stock offers value with room for upside if earnings momentum continues, though overbought technicals may prompt short-term consolidation.

Core Scientific (CORZ) trades at $21.18, up 8.95% in the last session, amid a technical bearish trend but strong analyst optimism. The company reported Q2 2026 revenue growth and a strategic AMD partnership for AI infrastructure, though it faces significant net losses and negative cash flow. Key support lies at $18, with resistance near $21.

The outlook is mixed: bullish analyst targets near $36 suggest upside potential from AI-driven contracts, but high cash burn and persistent losses pose risks. Investors should weigh growth prospects against financial sustainability, with sentiment hinging on execution of new deals and margin improvement.